Terry Chrisomalis - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Terry Chrisomalis's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Terry Chrisomalis
Verified
Author, Biotech Analysis Central, Seeking Alpha
Tampa Bay
Beats
History, Psychology Culture, TechnologyScience, Health Environment
fashion, politics
Content
By Terry Chrisomalis| Seeking Alpha@ SummaryTenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical milestones.
By Terry Chrisomalis| Seeking Alpha@ Apr. 15, 2025 2:37 PM ET, , , , , Summary13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
By Terry Chrisomalis| Seeking Alpha@ SummaryTenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical milestones.
Company Info
Seeking Alpha
Seeking Alpha is an online platform designed for investors, offering stock market analysis and opinions. Founded in 2004 and headquartered in Israel, with additional offices in New York, Ukraine, and India, it fosters a community where investors can share ideas, discuss news, and engage in financial conversations. The platform features crowdsourced investment analysis, publishing over 400 articles and news updates daily from more than 18,000 analysts. It also provides newsletters and Real-Time Alerts (RTA) subscriptions, catering to various investing styles, and has over 2.6 million subscribers. Additionally, Seeking Alpha offers free access to earnings transcripts and various subscription plans that include premium content and tools for informed investment decisions. Each month, the platform attracts around 20 million visitors, highlighting its popularity among individual investors.
New York, New York, United States
+1 212-497-1111
Founded: 2005